TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Laura Bingham As president of Peace College, it’s Laura Bingham’s job to ensure that each woman who enters the campus is educated and prepared to take on the world. if they’re trying to emulate Bingham, Peace students have found a good role model. feeds.bizjournals.com |
Arena’s Lorcaserin Has Safety Edge Zacks.com submits: Results from Arena’s (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups is at least 5% and the difference is statistically significant, or (2) the proportion of subjects who lose greater than or equal to 5% of baseline body weight in the active-product group is at least 35%, is approximately double the proportion in the placebo-treated group, and the difference between groups is statistically significant.Complete Story » seekingalpha.com |
Little Difference Between Roche's Avastin and Lucentis for Macular Degeneration The Burrill Report submits: By Kristi EatonA new study shows that a cancer drug is no different in effectiveness as a gold standard for macula degeneration. Researchers from Boston University School of Medicine and the VA Boston Healthcare System discovered there was no difference in efficacy between Genentech's (now Roche's (RHHBY.PK)) Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration after six months.Complete Story » seekingalpha.com |
GeneLink Reports Third Quarter Results (Business Wire) ORLANDO, Fla.----GeneLink, Inc. , a leading consumer genomics biotech company, today reported financial results for the fiscal 2009 three-month period ended September 30, 2009. us.rd.yahoo.com |
Clarient Acquires Applied Genomics, Inc. (PR Newswire) Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met. Â As a result of the merger, AGI has become a wholly-owned subsidiary of Clarient. Â us.rd.yahoo.com |